We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Novel Glycoprotein Biomarker Evaluated for Liver Fibrosis

By LabMedica International staff writers
Posted on 13 Apr 2020
Print article
Image: The HISCL-5000 is a fully automated immunoassay analyzer with a throughput of 200 tests per hour (Photo courtesy of Sysmex).
Image: The HISCL-5000 is a fully automated immunoassay analyzer with a throughput of 200 tests per hour (Photo courtesy of Sysmex).
The main pathological consequence of chronic liver diseases is the continuous deposition of collagen fibers, which causes progressive liver fibrosis, and eventually cirrhosis. Mild‐to‐moderate fibrosis is rarely diagnosed because the disease is asymptomatic in the early stage.

While liver biopsy is the current gold standard for determining the fibrosis stage, it not only has its own limitations, such as the risk of sampling error, high rates of interobserver differences, risk of complications, and the high cost but is also not well accepted by patients. The utility of a recently discovered a novel serum glycomarker for liver fibrosis has been studied.

Scientists at the Korean Health Promotion Research Institute (Seoul, Korea) determine the diagnostic performance of Mac‐2 binding protein glycosylation isomer (M2BPGi) in screening liver fibrosis using magnetic resonance elastography (MRE) as a reference standard and to compare it with using the aspartate aminotransferase‐to‐platelet ratio (APRI) and the Fibrosis‐4 index (FIB‐4) in health checkups. The 236 examinees comprised 103 with normal subjects, 100 with fatty liver, five with chronic liver disease, five with liver cirrhosis, and 23 with HBsAg (+) based on ultrasonography or abdominal computed tomography.

Venous blood was drawn after an overnight fast for health checkups that included complete blood count (CBC), biochemical measurements, and M2BPGi. CBC and biochemical parameters were measured using the Sysmex XE‐2100D analyzer (Sysmex, Kobe, Japan) and the Hitachi 7600 analyzer (Hitachi, Tokyo, Japan). The serum M2BPGi level was measured using a chemiluminescence enzyme immunoassay method on an automated immunoassay analyzer, the Sysmex HISCL‐5000.

The median (interquartile) values of the cutoff index (COI) for fibrosis stages F0 (normal liver stiffness), F1 (mild fibrosis), F2 (significant fibrosis), and ≥F3 (advanced fibrosis) were 0.49 (0.34‐0.61), 0.48 (0.38‐0.68), 0.64 (0.43‐1.03), and 1.01 (0.75‐1.77), respectively. The AUCs of the COI for the screening of fibrosis stage ≥F1, ≥F2, and ≥F3 were 0.591, 0.698, and 0.853, respectively. Using a threshold of 0.75 for COI to exclude advanced fibrosis had a sensitivity, specificity, and negative predictive value of 80.0%, 77.9%, and 98.9%, respectively. The AUC for excluding advanced fibrosis was better for M2BPGi than for FIB‐4 and APRI.

The authors concluded that COI of M2BPGi was useful for the screening of significant and advanced fibrosis in health checkups. Screening for liver fibrosis could identify examinees with pre-symptomatic chronic liver disease susceptible to interventions. M2BPGi could also be integrated into a clinical algorithm to help primary care units to identify patients who should undergo MRE for diagnosing significant and advanced fibrosis. The study was published on March 29, 2020 in the Journal of Clinical Laboratory Analysis.

Related Links:
Korean Health Promotion Research Institute
Sysmex
Hitachi


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.